(berahyaluronidase alfa + pembrolizumab)
Marketedupdated 2mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
indications
investigational
NSCLCMelanoma
all catalysts(5)
approval · 5
News(0)
no news has mentioned this drug yet
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that